These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 36872303)

  • 1. Cellular response to β-amyloid neurotoxicity in Alzheimer's disease and implications in new therapeutics.
    Zhang H; Li X; Wang X; Xu J; Elefant F; Wang J
    Animal Model Exp Med; 2023 Feb; 6(1):3-9. PubMed ID: 36872303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of monomeric and soluble aggregated Aβ in Down's syndrome and Alzheimer's disease brains.
    Gkanatsiou E; Sahlin C; Portelius E; Johannesson M; Söderberg L; Fälting J; Basun H; Möller C; Odergren T; Zetterberg H; Blennow K; Lannfelt L; Brinkmalm G
    Neurosci Lett; 2021 May; 754():135894. PubMed ID: 33848613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commentary: Abeta N- Terminal Isoforms: Critical contributors in the course of AD pathophysiology.
    Tekirian TL
    J Alzheimers Dis; 2001 Apr; 3(2):241-248. PubMed ID: 12214065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-β load and cognitive decline in Alzheimer's disease.
    Morawski M; Schilling S; Kreuzberger M; Waniek A; Jäger C; Koch B; Cynis H; Kehlen A; Arendt T; Hartlage-Rübsamen M; Demuth HU; Roßner S
    J Alzheimers Dis; 2014; 39(2):385-400. PubMed ID: 24164736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation.
    Hartlage-Rübsamen M; Bluhm A; Piechotta A; Linnert M; Rahfeld JU; Demuth HU; Lues I; Kuhn PH; Lichtenthaler SF; Roßner S; Höfling C
    Molecules; 2018 Apr; 23(4):. PubMed ID: 29673150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology.
    Schilling S; Zeitschel U; Hoffmann T; Heiser U; Francke M; Kehlen A; Holzer M; Hutter-Paier B; Prokesch M; Windisch M; Jagla W; Schlenzig D; Lindner C; Rudolph T; Reuter G; Cynis H; Montag D; Demuth HU; Rossner S
    Nat Med; 2008 Oct; 14(10):1106-11. PubMed ID: 18836460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy.
    Perez-Garmendia R; Gevorkian G
    Curr Neuropharmacol; 2013 Sep; 11(5):491-8. PubMed ID: 24403873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl-Peptidase Activity of Meprin β Links N-truncation of Aβ with Glutaminyl Cyclase-Catalyzed pGlu-Aβ Formation.
    Schlenzig D; Cynis H; Hartlage-Rübsamen M; Zeitschel U; Menge K; Fothe A; Ramsbeck D; Spahn C; Wermann M; Roßner S; Buchholz M; Schilling S; Demuth HU
    J Alzheimers Dis; 2018; 66(1):359-375. PubMed ID: 30320570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disturbed Ca2+ homeostasis increases glutaminyl cyclase expression; connecting two early pathogenic events in Alzheimer's disease in vitro.
    De Kimpe L; Bennis A; Zwart R; van Haastert ES; Hoozemans JJ; Scheper W
    PLoS One; 2012; 7(9):e44674. PubMed ID: 22970285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease.
    Morawski M; Hartlage-Rübsamen M; Jäger C; Waniek A; Schilling S; Schwab C; McGeer PL; Arendt T; Demuth HU; Rossner S
    Acta Neuropathol; 2010 Aug; 120(2):195-207. PubMed ID: 20383514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
    Pinheiro L; Faustino C
    Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients.
    Bridel C; Hoffmann T; Meyer A; Durieux S; Koel-Simmelink MA; Orth M; Scheltens P; Lues I; Teunissen CE
    Alzheimers Res Ther; 2017 Jun; 9(1):38. PubMed ID: 28587659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms.
    Hartlage-Rübsamen M; Morawski M; Waniek A; Jäger C; Zeitschel U; Koch B; Cynis H; Schilling S; Schliebs R; Demuth HU; Rossner S
    Acta Neuropathol; 2011 Jun; 121(6):705-19. PubMed ID: 21301857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid beta receptors responsible for neurotoxicity and cellular defects in Alzheimer's disease.
    Kam TI; Gwon Y; Jung YK
    Cell Mol Life Sci; 2014 Dec; 71(24):4803-13. PubMed ID: 25151011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of glutaminyl cyclase inhibitors for Alzheimer's disease.
    Coimbra JR; Sobral PJ; Santos AE; Moreira PI; Salvador JA
    Future Med Chem; 2019 Dec; 11(24):3179-3194. PubMed ID: 31838899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta.
    Cynis H; Scheel E; Saido TC; Schilling S; Demuth HU
    Biochemistry; 2008 Jul; 47(28):7405-13. PubMed ID: 18570439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid-β Variants and Structural Analysis by Solution NMR Spectroscopy.
    Dammers C; Gremer L; Neudecker P; Demuth HU; Schwarten M; Willbold D
    PLoS One; 2015; 10(10):e0139710. PubMed ID: 26436664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cysteine-Rich Repeat Domains 2 and 4 are Amyloid-β Binding Domains of Neurotrophin Receptor p75NTR and Potential Targets to Block Amyloid-β Neurotoxicity.
    Wang YR; Wang J; Liu YH; Hu GL; Gao CY; Wang YJ; Zhou XF; Zeng F
    J Alzheimers Dis; 2018; 63(1):139-147. PubMed ID: 29578485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease.
    Verdier Y; Zarándi M; Penke B
    J Pept Sci; 2004 May; 10(5):229-48. PubMed ID: 15160835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.